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Nasal extranodal periph-
eral NK/T-cell  lymphoma 
treated by the protocol 
NK/T-cell high-dose-meth-
otrexate L-asparaginase 
dexamethasone
To the Editor: Extranodal NK/
T cell lymphoma, a nasal type lym-
phoma, is a distinct entity by the 
WHO classification of lymphomas1 
with a frequency of less than 1% of 
all non-Hodgkin lymphoma (NHL) 
in the West2 and the North Africa3 
and an increased incidence in Asia.4 
Standard treatment is not well estab-
lished and anthracycline containing 
combination chemotherapy (CHOP) 
had less than 30% survival at 5 years 
in localized disease.5 We report a case 
of extranodal NK/T cell lympho-
ma, nasal type, treated initially with 
CHOP as a large cell lymphoma and 
then with high-dose methotrexate, 
L-asparaginase and dexamethasone 
as part of a multicenter phase II clini-
cal trial (GELA-GOELAMS) for 
extranodal NK/T cell lymphoma.
A 34-year-old man, a welder by 
profession for 17 years, was seen in 
September 2008 for a right unilateral 
nasal obstruction associated with re-
current epistaxis (Figures 1,2). There 
were no associated B symptoms and 
performance status was 1. Anterior 
rhinoscopy revealed a right nasal 
cavity ulcerated mass with bleeding 
on touch. There was no other abnor-
mal finding on physical examination 
with no peripheral adenopathy  or 
hepatosplenomegaly. The diagnosis 
of NHL was established after several 
attempts at biopsy due to secondary 
infection and necrosis. The pathology 
was reported as consistent with large 
cell NHL and available immunohis-
tochemistry showed lack of expres-
sion of CD20, CD3, and cytokeratin. 
Patient was staged as Ann Arbor 
stage IEA with no poor prognostic 
factors according to the International 
Prognostic Index. The patient was 
started on CHOP chemotherapy 
but after two cycles, he had a poor 
response with a significant increase 
of the initial lesion and extension to 
the right upper lip. A repeat biopsy 
showed a diagnosis of extranodal 
NK/T-cell lymphoma, nasal type 
with EBV+.
The patient was switched to 
combined treatment with metho-
trexate 3g /m2 on day 1, L-asparagi
nase 6000U/m2 on day 2, 4, 6 and 8 
with dexamethasone 40 mg day 1 to 
day 4 on 21 days cycle for a total of 
three cycles. The patient responded 
nicely and the tumor regressed after 
the first cycle. The patient achieved 
a complete clinical response after a 
second cycle (Figure 3). One month 
after the third cycle, he started ir-
radiation, 30 Gy to the initial site 
of the disease. At the time of last 
follow up at 24 months, he was 
in complete remission (Figure 4). 
In conclucion, extranodal NK/T-
cell lymphoma nasal type is a rare 
entity. Diagnosis may be difficult 
without an appropriate panel of im-
munohistochemistry that may not 
be available in all hospitals, especially 
the detection of cytoplasmic expres-
sion (CD3ε), EBV expression and 
molecular biology techniques. Cases 
with clinical suspicion of extranodal 
NK/T-cell lymphoma should have 
a full panel of immunohistochemis-
try from a tertiary referral center if 
needed. Conventional anthracyclin-
based thereapy (CHOP) has a poor 
outcome. This could be related to 
the overexpression of PGP (multi-
drug resistance) by NK/T tumor 
cells.6 Chemosensitivity to L-aspar-
aginase and high-dose methotrexate 
has encouraging results and should 
be tested in future prospective stud-
ies.7-8 Our patient had 17 years of 
occupational exposure to iron dusts 
and galvanized metals (welding) 
that may had contributed to the de-
velopment of this type of NHL In 
our patient .
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Figure 1. nasal damage at diagnosis. Figure 2. Large nasal damage before treatment.
Figure 3. improvement after treatment with high-dose 
methotrexate and L-asparaginase.
Figure 4. Complete clinical remission.
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